LIke ThisLIke ThisLIke This

Angeles Fernandez-Gonzalez, PhD

Angeles Fernandez-Gonzalez, PhD
Medicine Research
Newborn Medicine Research
Hospital Title:
Associate Scientific Researcher
Academic Title:
Instructor in Pediatrics, Harvard Medical School
Research Focus Area:
Pathobiology of the Lung During Development and Hypoxia
Contact Via Email
Send an email to SendYour Name*Your Email Address*Subject*Comments*

Research Overview

Dr. Fernandez-Gonzalez is interested in the pathobiology of the lung during developmental prematurity and inflammation, and the cellular pulmonary responses associated with the establishment of disease. In particular, she investigates the contribution of macrophage activation in mechanisms of lung injury and repair following exposure to noxious concentrations of oxygen in murine experimental models. Her ultimate goal is to examine new players related to the innate immune response that can be used as mediators of therapeutic action for the treatment of lung disease.

About Angeles Fernandez-Gonzalez

Dr. Fernandez Gonzalez received her PhD degree from University Alcala de Henares, Madrid, Spain. Prior to her appointment in 2003 as Instructor in Pediatrics at BCH and HMS, she completed her postdoctoral training at St. Jude’s Childrens Hospital. 


Publications powered by Harvard Catalyst Profiles
  1. Willis GR, Fernandez-Gonzalez A, Anastas J, Vitali SH, Liu X, Ericsson M, Kwong A, Mitsialis SA, Kourembanas S. Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation. Am J Respir Crit Care Med. 2018 Jan 01; 197(1):104-116.
  2. Mitsialis SA, Willis GR, Fernandez-Gonzalez A, Kourembanas S. Reply to: Exosome Treatment of Bronchopulmonary Dysplasia. How Pure Should Your Exosome Preparation Be? Am J Respir Crit Care Med. 2017 Nov 21.
  3. Vitali SH, Hansmann G, Rose C, Fernandez-Gonzalez A, Scheid A, Mitsialis SA, Kourembanas S. The Sugen 5416/hypoxia mouse model of pulmonary hypertension revisited: long-term follow-up. Pulm Circ. 2014 Dec; 4(4):619-29.
  4. Lee C, Mitsialis SA, Aslam M, Vitali SH, Vergadi E, Konstantinou G, Sdrimas K, Fernandez-Gonzalez A, Kourembanas S. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation. 2012 Nov 27; 126(22):2601-11.
  5. Hansmann G, Fernandez-Gonzalez A, Aslam M, Vitali SH, Martin T, Mitsialis SA, Kourembanas S. Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension. Pulm Circ. 2012 Apr-Jun; 2(2):170-81.
  6. Fernandez-Gonzalez A, Alex Mitsialis S, Liu X, Kourembanas S. Vasculoprotective effects of heme oxygenase-1 in a murine model of hyperoxia-induced bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2012 Apr 15; 302(8):L775-84.
  7. Vergadi E, Chang MS, Lee C, Liang OD, Liu X, Fernandez-Gonzalez A, Mitsialis SA, Kourembanas S. Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation. 2011 May 10; 123(18):1986-95.
  8. Liang OD, Mitsialis SA, Chang MS, Vergadi E, Lee C, Aslam M, Fernandez-Gonzalez A, Liu X, Baveja R, Kourembanas S. Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. Stem Cells. 2011 Jan; 29(1):99-107.
  9. Aslam M, Baveja R, Liang OD, Fernandez-Gonzalez A, Lee C, Mitsialis SA, Kourembanas S. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med. 2009 Dec 01; 180(11):1122-30.
  10. Vitali SH, Mitsialis SA, Liang OD, Liu X, Fernandez-Gonzalez A, Christou H, Wu X, McGowan FX, Kourembanas S. Divergent cardiopulmonary actions of heme oxygenase enzymatic products in chronic hypoxia. PLoS One. 2009 Jun 19; 4(6):e5978.
  11. Show all
  12. Fernandez-Gonzalez A, Kourembanas S, Wyatt TA, Mitsialis SA. Mutation of murine adenylate kinase 7 underlies a primary ciliary dyskinesia phenotype. Am J Respir Cell Mol Biol. 2009 Mar; 40(3):305-13.
  13. Angeles Fernandez-Gonzalez, Stella Kourembanas, Todd A. Wyatt , & S. Alex Mitsialis. Mutation of murine Adenylate Kinase 7 underlies a primary ciliary dyskinesia phenotype. Am. J. Res. Cell Mol. Biol. 2008; (Advanced Online Publication).
  14. A. Fernandez-Gonzalez, S. Kourembanas & S. A. Mitsialis. An animal model for Primary Ciliary Dyskinesia (PCD) based on the disruption of a novel murine gene. American Thoracic Society International Conference, San Francisco, California. 2007.
  15. Anttila V, Christou H, Hagino I, Iwata Y, Mettler BA, Fernandez-Gonzalez A, Zurakowski D, Jonas RA. Cerebral endothelial nitric oxide synthase expression is reduced after very-low-flow bypass. Ann Thorac Surg. 2006 Jun; 81(6):2202-6.
  16. Fernandez-Gonzalez A, Naghshineh S, Mitsialis A and Kourembanas S. . Heme Oxygenase-1 (HO-1) overexpression prevents fibrosis and iron deposition in developmental lung injury. American Thoracic Society International Conference, San Diego, California. 2006.
  17. Vesa Anttila,MD, Helen Christou,MD, Ikuo Hagino,MD, Yusuke Iwata, MD, Bret A. Mettler, MD, Angeles Fernandez-Gonzalez, PhD, David Zurakowski, PhD, and Richard A. Jonas, MD. Cerebral endothelial nitric oxide synthase expression is reduced after very low flow bypass. Ann. Thorac.Surg. 2006; 81:2202-2206.
  18. Vitali SH, Mitsialis SA, Christou H, Fernandez-Gonzalez A, Liu X, Kourembanas S. Mechanisms of heme oxygenase-1-mediated cardiac and pulmonary vascular protection in chronic hypoxia: roles of carbon monoxide and bilirubin. Chest. 2005 Dec; 128(6 Suppl):578S-579S.
  19. Fernandez-Gonzalez A, Naghshineh S, Mitsialis A and Kourembanas S. . Heme oxygenase-1 overexpression decreases alveolar remodeling and iron deposition in developmental lung injury. HO Conference: The fourth International Congress,Boston, MA. 2005.
  20. Fernandez-Gonzalez A, La Spada AR, Treadaway J, Higdon JC, Harris BS, Sidman RL, Morgan JI, Zuo J. Purkinje cell degeneration (pcd) phenotypes caused by mutations in the axotomy-induced gene, Nna1. Science. 2002 Mar 08; 295(5561):1904-6.
  21. Tomomura M, Fernandez-Gonzalez A, Yano R and Yuzaki M. Characterization of the apoptosis-associated tyrosine kinase (AATYK) expressed in the CNS. Oncogene. 2001; 20:1022-1032.
  22. Tharp R, Fernandez-Gonzalez A, Faherty C, Smeyne M, Parris, J, Morgan J I and Smeyne R. . Genetic and Environmental aspects of the MPTP model of Parkinson’s Disease. 7th National Parkinson foundation International Symposium on Parkinson’s disease research, San Diego, California. 2001.
  23. Fernandez-Gonzalez A, Pérez-Otaño I, Morgan JI. MPTP selectively induces haem oxygenase-1 expression in striatal astrocytes. Eur J Neurosci. 2000 May; 12(5):1573-83.
  24. Hamre KM, Tharp R, Fernandez-Gonzalez A, Smeyne RJ. . The role of genotype and sex MPTP-induced degeneration in the substantia nigra of mice. 27th American Society for Neuroscience, New Orleans, La. 1997.
  25. Fernandez-Gonzalez AL, España A, Redondo P. Solid tumors after heart transplantation. Ann Thorac Surg. 1996 Sep; 62(3):943-4.
  26. Fernandez GA, De Ceballos ML, Jenner, P, Marsden CD. Alterations in peptide levels In Parkinson’s disease and incidental Lewy Body disease. Brain. 1996; 119:823-830.
  27. Fernandez, GA, Jenner P, Marsden CD, and De Ceballos ML. Characterization of neurotensin-like immunoreactivity in human basal ganglia: increased neurotensin levels, in substantia nigra in Parkinson’s disease. Peptide. 1995; 16:339-346.
  28. Fernandez A, Schneider JS. . Factors affecting striatal dopamine release in normal, symptomatic and recovered MPTP-treated cats. An in vivo microdialysis study. 25thAmerican Society for Neuroscience, San Diego, California. 1995.
  29. De Ceballos ML, Fernandez GA, Jenner P, Marsden CD. Parallel alterations in metenkephalin and substance P levels in medial globus pallidus in Parkinson’s disease patients. Neurosci Lett. 1993; 160:163-166.
  30. De Ceballos ML, Fernandez MA, Jenner P, Marsden. . Basal ganglia neuropeptide alterations in Parkinson’s disease and controls bearing Lewy Bodies. Strategies for studying CNS active Compounds: Models, Screens and Clinical Syndromes, Madrid. 1992.
  31. De Ceballos ML, Fernandez MA, Jenner P, Marsden CD. . Neuropeptide receptors are decreased in basal ganglia from Parkinson’s disease patients. 7th International Cathecolamine symposium, Amsterdam. 1992.
  32. Fernandez GA, De Ceballos ML, Jenner P, Marsden CD. Striatal neuropeptide levels Parkinson’s disease patients. Neurosci Lett. 1992; 145:171-174.
  33. De Ceballos ML, Fernandez MA, Perez-Otano I, Del Rio J. . Distribution of Neuropeptides in human brain after HPLC purification. III Congress of the SEN, Sevilla. 1989.
  34. Fernandez-Moreno MD, Diaz-Juarez JL, Fernandez-Gonzalez MA, Sanchez- Franco F, Prieto JC. The vasoactive intestinal peptide receptor/effector system is developmentally regulated in rat jejuno ileal epithelial cells. Biochem. Int. 1988; 16:332-337.
  35. Fernandez-Moreno MD, Fernandez-Gonzalez MA, Lopez-Luna MP, Prieto JC. Interaction of insulin with small intestinal epithelial cells from developing rats. Biology of the Neonate. 1988; 54:280-293.
  36. Fernandez-Moreno, Fernandez-Gonzalez MA, Arilla E, Lorenzo MJ, Prieto JC. Ileal levels and VIP receptor/effector system in ileal epithelial cells after colectomy in the rat. Biochem. Med. Met. Biol. 1987; 38:213-218.
  37. Carmena MJ, Sancho JI, Fernandez-Gonzalez MA, Escudero F, Prieto JC . Somatostatin inhibits VIP and isoproterenol-stimulated cyclic AMP accumulation in rat prostatic epithelial cells. FEBS Lett. 1987; 218:73-76.
  38. Fernandez-Gonzalez MA, Barrios V, Sancho JI, Carmena MJ, Tresguerres JAF, Prieto JC. Tissue plasma distribution of exogenous growth hormone-releasing factor. Analogue after venous, subcutaneous and intraperitoneal injection in the rat. Gen. Pharmacol. 1987; 18:551-554.
  39. Fernandez-Moreno MD, Fernandez-Gonzalez MA, Prieto JC . Effect of starvation on insulin binding to rat intestinal epithelial cells. IRCS Med. Sci. Biochem. 1986; 14:715-716.
LIke ThisLIke ThisLIke This